Journal: Nature medicine
The DESTINY-Breast04 trial demonstrated that trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared to physician’s choice chemotherapy in patients with HER2-low metastatic breast cancer.
After a median follow-up of 32 months, median OS was:
- 22.9 months with T-DXd
- 16.8 months with chemotherapy (HR 0.69)
Similar OS benefits were observed in both hormone receptor-positive patients and exploratory hormone receptor-negative subgroups.
The safety profile of T-DXd was acceptable and manageable, supporting its use as the standard of care following prior chemotherapy in this patient population.